Nutritional Anaemia by Alhossain A. Khallafallah & Muhajir Mohamed
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Nutritional Anaemia 
1Alhossain A. Khallafallah1,2,* and Muhajir Mohamed1 
1Launceston General Hospital, Launceston, Tasmania 
2School of Human Life Sciences, University of Tasmania 
Australia 
1. Introduction 
Data available in Australia regarding the prevalence of iron deficiency anaemia (IDA) in 
pregnant women show that about 17.4% of pregnant women suffer from IDA, while the 
World Health Organization (WHO) global database on anaemia has suggested a prevalence 
of 14% based on a regression-based analysis.  
There is a suggested association between IDA and the following maternal risks: increased 
fatigue antenatally and postnatally, poor exercise tolerance, impaired thermoregulation, 
decreased resistance to infection, reduced tolerance of bleeding or surgical intervention at 
delivery, delayed instigation of lactation and increased risk of postnatal depression. IDA is 
also a risk factor for preterm delivery and subsequent low birth weight and may be 
associated with inferior neonatal health. Infants born to women with IDA are more likely to 
become anaemic themselves which, in turn, is known to have a detrimental effect on an 
infant’s mental and motor development. Although iron supplementation during pregnancy 
is one of the most widely practiced public health measures, there remain many controversial 
issues with this practice.  
Oral iron supplementation has long been a standard treatment for IDA worldwide.  However, 
patients do not always respond adequately to oral iron therapy due to difficulties associated 
with ingestion of the tablets and their side effects, which can play a significant role in rates of 
compliance. The side effects include gastrointestinal disturbances characterized by colicky 
pain, nausea, vomiting, diarrhoea, and or constipation, and occur in large cohort of patients 
taking iron preparations. In addition, the presence of bowel disease can affect the absorption of 
iron and thereby minimize the benefit received from oral iron therapy. 
 In the past, intravenous iron had been associated with undesirable and sometimes serious 
side-effects and was therefore limited in use. In recent years, the new type II and III iron 
complexes have been developed which are better tolerated and can be used for a rapid 
reversal of iron deficiency anaemia. Despite increasing evidence of the safety of the newer 
preparations, intravenous iron continues to be underutilized. 
1.1 Iron deficiency anaemia in the general population  
Anaemia occurs in different age groups in a number of clinical situations associated with 
iron deficiency, iron deficiency anaemia and blood loss.   Usually in the presence of intact 
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erythropoiesis iron therapy is very effective in restoring the depleted iron stores and 
accordingly improving the haemoglobin.   Other treatment strategies that stimulate 
erythropoiesis such as erythropoietin will also require the presence of iron in order to be an 
effective treatment.   Intravenous iron offers a rapid repletion of iron and is superior to oral 
iron as proven in many clinical trials. 
In this regard, we will describe different clinical scenarios for iron deficiency anaemia in 
different cohorts of patients and numerate the available management options in the 
literature.  
1.2 Other causes for nutritional anaemia 
In this part, we are discussing other common nutritional deficiencies apart from iron that 
result in anaemia such as vitamin B12 and folate deficiencies. Furthermore, we discuss rare 
nutritional anaemia due to copper and selenium deficiencies and highlighting the most 
appropriate management approaches and treatment strategies.  
2. Iron deficiency 
Nutritional iron deficiency is the most common deficiency disorder in the world, affecting 
more than two billion people worldwide, with pregnant women at particular risk.1-3 World 
Health Organization (WHO) data show that iron deficiency anaemia (IDA) in pregnancy is a 
significant problem throughout the world with a prevalence ranging from about 15% of 
pregnant women in industrialized countries to an average of 56% in developing countries 
(range 35-75%).2,3  
Furthermore, IDA is affecting a large number of children and women not only in the 
developing world, but is also considered the only nutrient deficiency that is significantly 
prevalent in the developed world too. The numbers of patients with ID and IDA are 
overwhelming as more than 2 billion people, over 30% of the world’s population, are iron 
deficient with variable prevalence, distribution and contributing factors in different parts of 
the world.1-3 
Iron deficiency affects more people than any other condition, constituting an epidemic 
public health crisis. It is usually present with subtle manifestations and sometimes 
considered as a chronic slowly progressing disease that is often underestimated and 
untreated worldwide despite several warnings and awareness efforts of the World Health 
Organisation.1-3 
It is worth noting that IDA has a debilitating effect as it reduces the work capacity of 
individuals and perhaps entire populations, with resultant serious economic consequences 
and obstacles to national development.1,4-6  
The high prevalence of IDA has substantial health consequences with subsequent socio-
economic hazards, including poor pregnancy outcome, impaired educational performance, 
and decreased work capacity and productivity.1,6 
Targeted iron supplementation, iron rich diet, or both, can improve iron deficiency. 
However, variability of bioavailable iron compounds limit its value against nutritional iron 
deficiency. Therefore, laboratory measures of iron stores should be utilised to determine 
iron deficiency and monitor the therapy.3,4,6 
Iron deficiency anaemia is quite often underestimated despite the high prevalence of iron 
deficiency. Blood loss is a major cause of anaemia in the general population.5,6 This review 
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highlights the importance of early diagnosis of IDA and hence offers the most appropriate 
treatment in order to avoid serious complications of anaemia.  
2.1 Causes of iron deficiency anaemia 
Nutritional iron deficiency generally arises when physiological requirements cannot be met 
by daily dietary iron ingestion as well as iron absorption. Religious beliefs in some countries 
and the dietary attitude of individuals may contribute to lack of iron supply when certain 
populations consume monotonous plant-based diets and hence reduces dietary iron 
bioavailability. 
Women are at particular risk for developing IDA especially in their childbearing period as 
they have greater iron requirement because of menstrual blood loss and also during the 
pregnancy and lactation period when they have increased iron demands.2 
Iron deficiency can also be caused by other types of chronic blood loss including gastro-
intestinal  blood loss from gastritis, peptic ulcers, inflammatory bowel disease, parasitic 
infestations (such as hookworms, Ancylostoma) as well as haemorrhoids.7  
The recommended dietary daily iron for men over the age of puberty and women over the 
age of menopause are 8 mg per day, while for women in the child bearing period the 
recommended daily dietary iron dose  is 18 mg per day.8  In the typical diet, major sources 
of iron are meat, poultry, nuts and seeds, legumes and bean products, green leafy 
vegetables, raisins, whole grains and fortified cereals.8  
2.2 Symptoms of iron deficiency 
The presenting symptoms of IDA are variable and usually are the general symptoms of 
anaemia, including lethargy; unusual fatigue after exertion; signs of iron deficiency 
including paleness of the skin or eyes, intestinal problems, cognitive problems such as 
impaired learning ability, spoon nails, easy brittle and fragile nails, leg cramps especially in 
night time (restless leg syndrome)  and sometimes hair loss.6,7 
2.3 Diagnosis of Iron deficiency 
Although a study of bone marrow iron stores is an accurate tool for assessing the body 
stored iron, it remains an impractical, invasive procedure to apply for most patients.  
Measurement of both soluble transferrin receptor and serum ferritin provide a tool for 
accurate diagnosis of IDA.  However, transferrin receptor is not a well-standardized test that 
can be reliably reproduced with high precision in most of laboratories worldwide.  
In the meantime, ferritin estimation is an easy automated test to perform in most 
laboratories in the world; however its use is limited in case of inflammation or infection as it 
is considered as an acute phase reactant that is affected by many conditions including 
inflammation or infection and hence negatively influences its value.  
Therefore, new technology such as hypochromic reticulocytes and reticulocyte haemoglobin 
testing, reportedly have higher sensitivity, specificity, reproducibility and cost effectiveness 
as a screening tool for iron deficiency.9,10 This may offer a reliable screening test for iron 
deficiency in the future.  
2.4 Iron metabolism 
The main source of iron in humans comes from the destruction of erythrocytes by 
macrophages of the reticuloendothelial system including the spleen (recycled internal iron 
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supply), while the daily requirement of external iron remains as little as between 1 to 8 mg 
daily.  However, more external iron is required in case of increased demand for iron such as 
physiological requirements during growth, pregnancy or in a pathological condition such as 
bleeding (increase iron loss).3,4,6,8 Recent studies have shown how the human body up- and 
down-regulate iron absorption in response to changing iron status via intestinal and hepatic 
proteins.6,10  
Transferrin is an important protein synthesized by the liver that provides both a high 
affinity and high avidity mechanism to increase iron yield required for active 
erythropoiesis.11 
Hepcidin is a peptide hormone that is also synthesized by liver that regulates iron and plays 
a significant role in iron metabolism.12–15  Hepcidin was first described in January 1998 by 
Tomas Ganz and colleagues,12 who sequenced this peptide and found that it contained 25 
amino acids and 4 disulfide bonds. This peptide circulates in the plasma and responds to 
various stimuli that regulate iron stores and serum iron and is usually renally excreted.13  
Ferroportins are considered as hepcidin receptor/iron exporter in the regulation of iron 
absorption, recycling, and tissue distribution. Ferroportin 1A (FPN1A) works as an element 
for translational repression in iron-deficient cells, while FPN1B is expressed in duodenal 
enterocytes, enabling them to export iron.12 
Hepcidin, controls ferroportin and hence, the inflows of iron into plasma from main sources; 
duodenal enterocytes absorbing iron intake and from macrophages involved in the recycling 
of iron as well as from hepatocytes involved in iron storage.12-15 
During pregnancy, fetal hepcidin controls the placental transfer of iron from maternal 
plasma to the fetal circulation. When hepcidin concentrations are low, iron enters blood 
plasma at a high rate. When hepcidin concentrations are high, ferroportin is internalized, 
and iron is trapped in enterocytes, macrophages, and hepatocytes.14,15  
Plasma iron concentrations and transferrin saturation are usually reflecting the difference 
between the hepcidin and ferroportin-regulated transfer of iron to plasma and iron 
consumption by the erythropoietic bone marrow tissue and, to a lesser extent, other tissues.  
Although, plasma transferrin compartment is considered relatively small, its iron content 
turns over every few hours, allowing iron concentrations to respond rapidly to changes in 
hepcidin concentrations.12-15  
The role of hepcidin is mainly to regulate the absorption of dietary haeme, which is the main 
form of absorbable iron in human. Usually haeme is metabolized to ferrous iron by the 
enterocytes, however, its transfer to plasma will require ferroportin and hence is subjected 
to hepcidin-regulation.12-15 
2.5 Treatment of iron deficiency anaemia 
Although oral iron therapy is the most widely practiced treatment for iron deficiency 
anaemia, there are many issues that limit oral iron success in the management of IDA. 
For instance, many patients do not respond adequately to oral iron therapy due to 
difficulties associated with ingestion of the tablets and their side effects, which can play a 
significant role in rates of compliance.16-17   
The side effects of oral iron therapy include gastrointestinal disturbances characterized by 
colicky pain, nausea, vomiting, diarrhoea and or constipation, and occur in about 50% of 
patients taking iron preparations.6   
Furthermore, the most widely prescribed oral iron is mainly composed of ferrous salts.18,19 
Ferrous salt is characterized by low and variable absorption rates and also its absorption can 
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be limited in conjunction with ingestion of certain foods as well as mucosal luminal 
damage.18-21 Therefore, ferric compounds were introduced to avoid such obstacles. 
However, these compounds are generally less soluble and have poor bioavailability.21  
The usual recommended oral iron sulphate dose for the treatment of iron deficiency should 
be at least 80 mg daily of elemental iron, which is equivalent to 250 mg of oral iron sulphate 
tablets (Abbott, Australasia Pty Ltd).  
In addition to oral iron side effects, patients with chronic bowel disease do not absorb oral 
iron readily and thereby minimise the benefit received from oral iron treatment.21  
Although it is debatable whether intravenous iron should be administered or would oral 
iron have the same effect, many queries remain and are required to be addressed in further 
research and randomised trials.  
The major challenges in the management of IDA are related to the tolerability and side 
effects of iron therapy in its different forms. Therefore, it is crucial to determine the most 
appropriate form and dose of iron as well as duration of treatment in order to successfully 
replenish the iron stores.  Traditionally, the oral iron was widely used worldwide, however  
the effectiveness of oral formulations, due to the several facts mentioned before, is 
compromised by lack of absorption, poor compliance, adverse effects (up to 56%) and 
discontinuation of treatment (up to 20%).6,18,21 
On the other hand, parenteral iron seems to be an attractive alternative to oral iron and is 
likely to be more popular option due to the introduction of new intravenous iron 
preparations, which allow high doses of iron to be administered rapidly in a single 
treatment. 
In the past, intravenous iron had been associated with undesirable and sometimes serious 
side-effects and was therefore limited in use.22-23 However, in recent years, the new type II 
and III iron complexes have been developed which are better tolerated and can be used for 
rapid repletion of iron stores.24,25 Despite increasing evidence of the safety of the newer 
preparations, both in pregnant and general populations, intravenous iron continues to be 
underutilised because of previous concerns with tolerability of older intravenous iron 
preparations.26 
Review of infusions of iron dextran among 481 patients revealed that about 25% of patients 
had mild side effects that have been self-limited. However about 2% experienced severe 
allergic reactions and about 0.6% were considered as anaphylactic reactions. Most of these 
reactions occurred immediately during the infusion of the test dose.27  
On the other hand,  iron gluconate is considered to have a lower reaction rate and therefore 
a test dose is not recommended. During the 1990s, only  3.3 allergic events per million doses 
per year with iron gluconate were reported.28   During mid 1970s to mid 1990s There were no 
life-threatening reactions recorded as a result of iron gluconate infusion.  
In contrast, during the same period, there were 31 fatalities among 196 allergic/anaphylactic 
reactions were reported for iron dextran, with about 16%  of case fatality rate.28  
The high incidence of adverse reactions of iron dextarn including serious adverse events 
have limited its application in practice.29-31  Nonetheless, the application of iron gluconate is 
considered safe, it remains impractical in theory as it requires multiple infusions with huge 
implications on the often-limited health system resources as well as on patients’ compliance.   
There are new forms of intravenous iron that have recently been developed and are 
available in some countries that permit treating physicians to administer safely relatively 
high doses of iron in a single dose treatment.  Furthermore, relatively older and established 
iron preparation such as intravenous iron polymaltose (Ferrosig, Sigma Pharmaceuticals, 
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Australia) demonstrated a high safety profile in treatment of IDA in both obstetric and 
general populations without a maximum dose-limit for treatment of IDA.26 The total dose of 
IV iron polymaltose is calculated according to the patient’s body weight and entry Hb level 
according to the product guidelines as following; iron dose in mg (50 mg per 1 ml) = body 
weight (maximum 90 kg) in kg x (target Hb (120 g/L) - actual Hb in g/L) x constant factor 
(0.24) + iron depot (500).26 Recent reports demonstrate the feasibility of rapid infusion over 2 
hours.26,32,33 However, a test-dose of iron polymaltose (100 mg) should be first administered 
over 30 minutes and premedication is recommended prior to iron treatment for better 
toleration (antihistamine and or low dose steroids).2632,33  
Furthermore, in 2009, the United States Food and Drug Administration (FDA) approved 
ferumoxytol (AMAG Pharmaceuticals, Inc., USA)34 for the treatment of iron-deficiency 
anaemia in adult patients with chronic kidney disease (CKD).34  However, the maximum 
dose allow only 510 mg of ferumoxytol in a single administration and is limited to use 
initially in CKD, although with the  expected expansion of its spectrum to include other 
forms of IDA.35   Another form of iron is ferric carboxymaltose (Vifor Pharma, Glattbrugg, 
Switzerland), which can  be rapidly administered in 15 minutes in doses of 15 mg/kg body 
weight, with a maximum dose of 1000 mg.36,37 There is no need for a test-dose of  ferric 
carboxymaltose and its use is not restricted as ferumoxytol.  More recently, in July 2010 a 
new intravenous  iron isomaltoside (MonoFer, Pharmacosmos A/S, Holbaek, Denmark)38 is 
introduced without the requirement of a test dose and it can be administered in 60 minutes 
at a rate of 20 mg/kg body weight in a single infusion without a maximum dose.38,39  Iron 
isomaltoside administration was effective, safe, and was well tolerated when used to 
replenish iron stores in patients with anaemia of CKD.39  
Intravenous iron including iron sucrose was employed in randomised controlled trials with 
improved effectiveness of intravenous iron only or in combination with oral iron compared 
to oral iron only based on Hb levels.40,41 
A single IV iron sucrose dose has been reported to produce an increased incidence of 
thrombosis (9/41; 22%).42 In contrast, 6 small doses of intravenous iron sucrose were 
administered over a three-week period without infusion-associated thrombosis as 
intravenous iron sucrose was administered in 5 daily doses to 45 pregnant women, also well 
tolerated.34 In the first study, utilising intravenous iron sucrose, there was no significant 
difference between intravenous iron sucrose versus oral iron sulphate in the Hb levels at 
any time as measured at days 8, 15, 21, 30 and at delivery,42 while in the second trial, with 
the 6 small doses of iron sucrose, there was a significant difference in Hb levels in favour of 
the intravenous iron sucrose group as measured at 2 and 4 weeks after administration of IV 
iron and at delivery.40 
However, both trials administered IV iron sucrose at the expense of a vastly greater effort 
from the patients as well as extra demands on hospital resources.40,41  
Certainly, the new intravenous iron preparations represent a medical revolution in  
effective, rapid and safe iron repletion in the management of iron deficiency anaemia.34-39 
This will reflect positively in the treatment of IDA in different populations by application of 
a single high-dose intravenous iron treatment with subsequent repletion of the iron stores 
effectively and hence, to improve subjective and objective outcomes in IDA.  
Although iron deficiency is a precursor of IDA, many clinical studies treat it similarly to 
IDA. In case of severe IDA, a blood transfusion has been the traditional efficient approach to 
correct the anaemia, especially if patients did not respond to oral iron therapy or when a 
rapid correction of anaemia is clinically required.   
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Currently, the development of new intravenous iron formulations that offer higher doses in 
a single administration has provided the treating physicians with the opportunity to employ 
intravenous iron as an effective, rapid and safe treatment for IDA34-39 avoiding the use of 
blood transfusion with its known hazards.43  There are increasing evidence-based research 
that support the safety and efficacy of IV iron in IDA.  There is also increasing evidence for 
inadequacy of oral iron in terms of adverse effects, lack of compliance as well as lack of 
absorption and slow and often questionable effect in IDA patients, especially in patients 
with ongoing blood loss.44-47  
A common requirement across the range of clinical situations is the need for safe, effective 
higher, less frequent doses to achieve optimal clinical outcomes.  The major goals of such 
strategy include overall cost reduction, relief to overstretched health system(s),  improved 
patient convenience, improved compliance, preservation of venous access and reduced 
blood transfusion.35-41,43,46  This will ultimately reduce the demand for blood transfusions, 
especially in the case of short supply. Furthermore, some of the new iron preparations such 
as ferric carboxymaltose and iron isomaltoside, do not require a test dose and therefore, ease 
the application of intravenous iron in a timely and cost effective fashion.  This certainly will 
enhance the use of intravenous iron in clinical practice.   
The WHO identified the problem of IDA as the most debilitating nutritional deficiency 
worldwide in the twenty first century. Such problem, if left untreated and not addressed 
properly can have a devastating effect on entire populations with adverse socio-economical 
consequences.  Therefore, the use of intravenous iron should be considered as an effective, 
rapid and safe treatment option in some clinical scenarios with intravenous iron being 
employed to avoid or reduce the demand for blood transfusions or when rapid repletion of 
iron stores are required. Treatment options for IDA should consider the recently developed 
intravenous iron formulations, which is considered a milestone in the management of IDA. 
Overall, the developing world is most vulnerable, especially the poorest and the least 
educated countries that are disproportionately affected by iron deficiency, and therefore 
they will gain the most by eradication of IDA. Therefore, awareness of the magnitude and 
scale of the IDA problem will help in recognising the most appropriate ways of diagnosis 
and treatment, which is crucial to overcome such devastating health problem. Perhaps 
consensus guidelines set by world experts in managing IDA incorporating new intravenous 
iron therapies are warranted.  
3. Vitamin B12 deficiency anaemia 
Cobalamin (vitamin B12) along with folic acid is normally required for DNA synthesis.  
Deficiency of one or both can cause defect in DNA synthesis, with lesser defect in RNA and 
protein synthesis, leading to a state of unbalanced cell growth and impaired cell division. 
The aberrant DNA synthesis causes arrest in S phase of cell cycle, affecting mitosis and cell 
division. This results in nucleo-cytoplasmic asynchrony and megaloblastic anaemia. 1 
3.1 Cobalamin 
Cobalamin is a complex organo-metallic compound in which the cobalt atom is situated 
within a corrin ring. The two active coenzyme forms are methylcobalamin and 5- 
deoxyadenosyl cobalamin1. 
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3.2 Main functions of cobalamin
2
 
1. Conversion of methyl malonyl coA to succinyl coA in the mitochondria.  
2. Methylation of homocysteine to methionine in the cytoplasm. 
3.3 Effects of cobalamin deficiency 
a. Impairment of DNA synthesis 
Cobalamin deficiency causes reduced methionine, which leads to reduced 
tetrahydrofolate and high methyl tetrahydrofolate in the cells (methyl folate trap 
hypothesis). This in turn causes low dTMP synthesis with high dUMP levels which 
results in impairment of DNA synthesis due to uridine for thymidine substitution in 
base pairing. 
b. Defective myelin synthesis and neurological problems.  
Cobalamin and folate have fundamental roles in CNS function at all ages, especially the 
methionine-synthase mediated conversion of homocysteine to methionine, which is 
essential for nucleotide synthesis and genomic and non-genomic methylation3. 
Prolonged cobalamin deficiency causes defective conversion of propionate to succinyl 
coA and also causes high serum methyl malonic acid and homocysteine. Both of these 
can cause defective myelin synthesis and neurological dysfunction, since methionine is 
required for synthesis of choline. 
c. Venous and arterial thrombosis. 
Plasma homocysteine levels are increased in both folate and cobalamine, which can      
lead to venous and arterial thrombosis4. 
3.4 Sources of cobalamin and  dietary requirements 
Cobalamin cannot be synthesized in human beings and needs to be supplied in the diet. 
Animal sources like meat, liver, fish, egg, milk and cheese are good sources of cobalamin.  
The estimated daily requirement of cobalamin is 1 mcg/day. The recommended daily 
allowance is 2.4 mcg/day. The daily requirement is so small relative to stores that deficiency 
typically takes years to develop in adults.5 
3.5 Absorption, transport and cellular uptake 
Absorption: 
1. Stomach  
Gastric digestion releases cobalamin from the bound proteins. Gastric R-binder (also 
called haptocorrin) binds with cobalamin forming cobalamin - R binder complex. R-
binder is also present in saliva, milk, gastric juice, bile, plasma and phagocytes. 
2. Duodenum:   
Cobalamin - R binder complex is digested by pancreatic proteases. Cobalamin binds to 
Intrinsic Factor (IF). IF is produced by gastric parietal cells and is resistant to proteolytic 
digestion. IF has two binding sites, one for cobalamin and another for cubulin in Ileal 
cells. 
3. Distal ileum:  
In the Ileal mucosal cell, IF is bound to cubulin. IF is destroyed and cobalamin binds to 
TCII forming a complex and absorbed into the blood.  
4. Blood:   
Cobalamin – TCII complex in the blood is rapidly taken up by liver, bone marrow and 
other cells. Most cobalamin in the blood is bound to TCI, present in secondary granules 
of neutrophils, a group closely related to R binder. The function of TCI is not known. 
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5. Cellular uptake:  
Cobalamin – TCII complex is rapidly taken up by liver, bone marrow and other cells. 
Cobalamin – TCII is released into lysosomes.   Lysosomal degradation leads to 
cobalamin release. Most of the cobalamin (~95%) is bound to two intracellular 
enzymes.  
a. Methyl malonyl coA mutase in the mitochondria catalyses methyl malonyl coA to 
succinyl coA. 
b. Methionine synthase in the cytosol: Methyl cobalamin acts as coenzyme for methionine 
synthase allowing transfer of methyl group from homocysteine to methionine. 5 methyl 
tetrahydrofolate donates methyl group to cobalamin thus regenerating methyl cobalamin. 
3.6 Causes of cobalamin deficiency 
a. Nutritional cobalamin deficiency:  
Causes:  Strict vegans, 6 breast-fed infants of mothers with low cobalamin levels. 
b. Cobalamin malabsorption 
1. Intrinsic Factor deficiency 
Pernicious anaemia 
Total gastrectomy 
2. Food-bound cobalamin malabsorption (FBCM)  
Gastritis can cause FBCM. Progression of anaemia is slower than in IF-related malabsorption 
and may extend beyond a decade. 7 
3. Disorders  causing cobalamin malabsorption in small intestine: 
- Pancreatic insufficiency 
- Blind loop syndrome 
- Fish tape worm (Diphyllobothrium latum) 
- Mucosal damage : 
Causes: Tropical sprue, nontropical sprue, Crohn’s disease , Small intestinal tumours like 
lymphoma, granulomatous disease. 
4. Other causes of cobalamin deficiency 
Gastric achlorhydrria 
Partial gastrectomy 
- Drugs: H2 receptor antagonists, proton pump inhibitors, Cholestryamine, Neomycin 
etc. 
3.7 Perinicious Anaemia (PA) 
PA is the most common cause of cobalamin deficiency is intrinsic factor deficiency due to 
atrophic gastritis or autoimmune destruction of parietal cells. The age of onset is usually 
after 40 years and more common in Northern European descent.  
In autoimmune PA, the gastric parietal cells are affected by cytotoxic T cells. There is an 
increased incidence of circulating antibodies – antiparietal cell antibodies (90%) & anti-
intrinsic factor antibodies (60%). PA can be associated with other autoimmune disorders 
like Grave’s disease, Hashimoto’s thyroiditis, Addison’s disease and hypo-
parathyroidisim.   
Gastric atrophy affects acid and pepsin areas of the stomach while the antrum is spared.  
Atrophic gastritis usually precedes the onset of megaloblastic anaemia by many years. All 
www.intechopen.com
 Anemia 138 
the cells which have a high proliferation exhibit megaloblastic changes, e.g.  epithelial cells 
lining the gastrointestinal tract (buccal mucosa, tongue and small intestine), cervix, vagina, 
and uterus. There is a higher risk of gastric cancer and carcinoids in patients with pernicious 
anaemia.8 
3.8 Clinical features of cobalamin deficiency 
Haematologic:  Pancytopenia with megaloblastic anaemia 
Cardiopulmonary:  Congestive heart failure 
Gastro-intestinal: Beefy red tongue (glossitis), broad spectrum malabsorption, diarrhoea 
Skin: Melanin pigmentation, premature greying of hair 
Genitals: Cervical and uterine dysplasia 
Reproductive:  Infertility or sterility 
3.9 Central nervous system (CNS) 
CNS involvement is unique to cobalamin deficiency. Peripheral nerves, posterolateral 
columns of spinal cord, cerebrum, optic nerve and rarely autonomous nervous system are 
affected. Pathological changes are demyelination, axonal degeneration and neuronal death. 
Symptoms are paraesthesia, numbness in extremities, weakness and ataxia.  Psychotic 
changes can occur in cobalamin deficiency, which can vary from mild irritability and 
forgetfulness to severe dementia or frank psychosis. 
3.10 Lab investigation in megaloblastic anaemia 
3.10.1 Full blood count & blood film 
High MCV usually precedes anaemia. Low red cell count, Hb and reticulocyte counts are 
common. Low white cell count and low platelet counts can occur in moderate to severe 
deficiency. 
Blood film shows macro-ovalocytes, hypersegmented neutrophils (greater than 5% PMNs 
with more than five lobes or a single PMN with more than six lobes are pathognomonic).  In 
severe deficiency, leuko-erythroblastic blood picture, tear drop poikilocytes, basophilic 
stippling, Howell Jolly bodies, nucleated red cells and Cabot’s ring can be seen. 
3.10.2 Bone marrow analysis 
Hypercellularity is prominent in all the three cell lines. Erythroid hyperplasia is more 
marked than the others. Abnormal erythropoiesis with abnormally large red cell precursors 
(megaloblasts) with less mature nuclei (nuclear – cytoplasmic asynchrony) is common. 
Nuclear chromatin is more dispersed with fenestrated pattern, a characteristic feature of 
megaloblastic anaemia. 
In severe megaloblastic anaemia up to 90% of RBC precursors are destroyed before they 
become mature, when compared to 10 % in normal marrow (ineffective erythropoiesis). 
Abnormal leucopoiesis - giant metamyelocytes and band forms are characteristic. 
Hypersegmented neutrophils are also seen in bone marrow. Abnormal megakaryocytes can 
be seen (pseudohyperdiploidy). 
3.10.3 Serum cobalamin levels
9
 
Normal levels : 120 - 680 pmol/L measured using Immunoassay. 
The limitations of serum cobalamin levels are 
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Falsely low levels (in patients with normal cobalamin) 
Severe folate deficiency (in 30% of patients) 
Low TC- I levels 
Physiologically low levels in pregnancy 
Intake of large doses of Vitamin C 
Falsely normal or  high levels (in patients with low cobalamin) 
Myeloproliferative disorders (Cobalamin binders like TC-I &TC-II are increased) 
Acute liver disease (release of cobalamin from hepatocytes). 
3.10.4 Other tests 
3.10.4.1 Schilling test 
The Schilling test measures cobalamin absorption by assessing increased urine radioactivity 
after an oral dose of radioactive cobalamin. Malabsorption due to any cause produces low 
radioactivity in urine. The test is useful in demonstrating that the anaemia is caused by an 
absence of IF. Schilling test helps to identify abnormal IF-related absorption and also to 
distinguish between gastric and intestinal defects.  
If the Schilling test result is normal, non-malabsorptive disorders and FBCM are considered. 
A modified absorption test, in which the test dose of cobalamin is bound to food, was 
created specifically to identify FBCM.10 
3.10.4.2 Serum homocysteine and methyl malonic acid 
Elevated serum methylmalonic acid and homocysteine levels are found in patients with 
cobalamin deficiency. Clinical deficiency often features serum MMA above 1000 nmol/L 
and homocysteine above 25 uM.  In folate deficiency, serum methylmalonic acid levels are 
normal and homocysteine levels are high.11, 12,13 
 
Patient Condition Homocysteine Methylmalonic Acid 
Healthy Normal Normal 
Vitamin B-12 deficiency Increased Increased 
Folate deficiency Increased Normal 
Table 1. Serum homocysteine and methylmalonic acid values in healthy persons, cobalamin 
and folic acid deficiency 
The advantage of these tests is they measure tissue vitamin stores and may diagnose the 
deficiency even when the serum cobalamin and folate levels are borderline or normal. 
3.10.4.3 Other tests 
1. The indirect bilirubin level may be elevated because pernicious anaemia causes 
haemolysis associated with increased turnover of bilirubin. The serum lactic 
dehydrogenase (LDH) concentration usually is markedly increased. 
2. Intrinsic Factor (IF) antibodies in serum by Immunoassay.14 
3. Type 1 (blocking) antibody prevents the attachment of vitamin B12 to intrinsic factor: 
present in 50-60% of patients with pernicious anaemia. Type 2 (precipitating) antibody 
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prevents attachment of the vitamin B12-intrinsic factor complex to ileal receptors: 
present in 30% of patients with pernicious anaemia, and only in those who also have 
Type 1 antibodies. IF antibody has high specificity for PA (>95%). It is used to help 
diagnose when pernicious anaemia is suspected. As recent vitamin B12 administration 
is associated with a high rate of false positive results the sample must be collected prior 
to commencing therapy or at least one week after vitamin B12 administration. This test 
shows rarely false positivity in diabetes and thyroid disorders. 
4. Parietal cell antibodies 
Parietal cell antibodies can be measured using indirect IF. Antibodies react with sub-units of 
the gastric parietal cell proton pump. Antibodies are positive in 80% of patients with 
pernicious anaemia and in 40-50% of patients with other organ specific autoimmune 
diseases.15 
4. Treatment 
4.1 Cobalamin deficiency 
4.1.1 Specific replacement therapy 
The 1000-mcg intramuscular dose begins repletion of stores (up to 150 mcg is retained from 
that injection by most patients).5 Cyanocobalamin and hydroxocobalamin are commonly 
available preparations. 8 to 10 injections are given over the first 2 to 3 months followed by 
monthly injections.16 Hydroxocobalamin injections can be spaced at twice the interval for 
cyanocobalamin.17 The toxicity of cobalamin is minimal with rare allergic reactions which 
can be anaphylactic.18 
In a randomized study with cobalamin deficiency, 2 mg of cyanocobalamin administered 
orally on a daily basis was as effective as 1 mg administered intramuscularly on a monthly 
basis.19 For patients who refuse monthly parenteral therapy or prefer daily oral therapy or in 
those with disorders of haemostasis, cobalamin (1–2 mg/day as tablets) can be 
recommended for patients with cobalamin malabsorption (where cobalamin is passively 
absorbed at high doses).1 
Patients with FBCM may need to take cobalamin supplements on an empty stomach to 
prevent in vitro binding of cobalamin to food. 1000 mcg oral doses may be necessary in 
many cases of FBCM, but the undesirable effects of long term high doses, if any, are not 
known.20 
4.1.2 Response to treatment 
The response to treatment is generally predictable and can be used as a therapeutic trial. 
Patients have a sense of well-being within 12 to 24 hours, which is an early feature of 
response. In bone marrow the megaloblastic erythropoiesis starts changing to normoblastic 
within 12 hours and  complete resolution by 48 hours. Brisk reticulocytosis starts at 3 to 4 
days and peaks at 5 to 7 days. Hypersegmented neutrophils continue to remain in the blood 
for 10 to 14 days. Mean corpuscular volume (MCV) will take eight weeks or more to 
normalize.1 All these responses will be impaired if there is associated iron deficiency, 
anaemia of chronic disease or hypothyroidism. 
Neurologic improvement also begins within the first week and is typically complete in 6 
weeks to 3 months. Its course is not as predictable as a haematologic response. Severe 
hypokalemia can occur after cobalamin therapy, which requires careful monitoring and 
management. 
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4.1.3 Causes of non-responsiveness of megaloblastosis to medication 
1. Wrong diagnosis (eg: Myelodysplastic syndrome) 
2. Combined cobalamin + Folate deficiency ,medication with one vitamin 
3. Drugs eg: Hydroxyurea, azathioprine 
4. Factors associated with B12 deficiency causing impaired response 
c. Iron deficiency 
d. Haemoglobinopathy  
e. Hypothyroidism  
4.2 Transfusions 
Complications can occur during transfusions, particularly congestive heart failure in elderly. 
Transfusion should be restricted to symptomatic anaemia, rather than by low haemoglobin 
values. In severe anaemia, exchange transfusion after removing 250- 300ml of anaemic blood 
and replacing packed red cells may be beneficial. 
4.3 Maintenance regimens 
High dose cobalamin tablets (1000 mcg) can be used for maintenance therapy. Despite the 
advantages of ease, cost, and comfort, oral therapy has its own limitations. Oral cobalamin is 
less effectively absorbed after a meal than when fasted.21 Monthly parenteral cobalamin 
injections are a better alternative in patients who are non-compliant with oral therapy. 
4.4 Cobalamin prophylaxis in clinical practice 
The value of general supplementation or dietary fortification with cobalamin are not 
proven.22 In some situations, like strict vegetarians, patients with gastric surgery and in 
elderly persons, life-long supplementation with cobalamin will be essential.  
5. Folate deficiency anaemia 
Folic acid is also known as pteroyl-monoglutamic acid. Fruits and vegetables constitute the 
main dietary source of the vitamin. Dietary folic acid is heat labile and may be destroyed by 
cooking. The daily requirement is usually about 50 mcg. The requirement may be increased 
to many folds during pregnancy.  
Folates in various foodstuffs are largely conjugated as polyglutamates.  Conjugases in the 
lumen of the gut convert polyglutamates to mono- and diglutamates, which are readily 
absorbed in the proximal jejunum. Plasma folate is primarily in the form of N5-
methyltetrahydrofolate which is a monoglutamate and is transported into cells by a carrier. 
In the cell, the N5-methyl group is removed and the folate is then converted again to the 
polyglutamate form. Conjugation to polyglutamate may be useful for retention of folate 
within the cell.  
The normal body store of folic acid is 5 to 20 mg.  Nearly 50% of the body stores are present 
in the liver. Folate deficiency usually occurs within 4 to 5 months with dietary deficiency, in 
contrast to cobalamin deficiency which takes many years.  
5.1 Role of folate in DNA synthesis 
Folate serves as an intermediate carrier of 1 carbon fragment and is essential for denovo 
synthesis of purines, dTMP and methionine. Its active form is tetrahydrofolate, which 
acquires 1 carbon from serine and converted to glycine.  
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For purine synthesis, the 1 carbon is oxidised to formic acid, then transferred to substrate. 
For methionine synthesis, cobalamin is required and 1 carbon fragment is reduced to the 
level of methyl group, which is then transferred to homocysteine. In these reactions, the 
cofactor is released as tetrahydrofolate which can immediately participate in another 1-
carbon transfer cycle. 
Conversion of dUMP to dTMP is catalysed by thymidylate synthase and dihydrofolate is 
released. To participate in further 1- carbon transfer cycle, the dihydrofolate is catalysed by 
dihydrofolate  reductase to tetrahydrofolate. 
5.2 Folate deficiency 
5.2.1 Causes 
1. Inadequate intake  
Alcoholics, infants, anorexia nervosa, malnutrition, prolonged cooking of vegetables. 
2. Increased requirements  
a. Pregnancy and lactation 
b. Infancy and childhood 
c. Haemolytic anaemias 
d. Cancers 
e. Exfoliative dermatitis 
3. Malabsorption 
a. Tropical sprue and non-tropical sprue 
b. Partial gastrectomy 
c. Crohn’s disease 
d. Intestinal Lymphoma 
4. Impaired Metabolism 
a. Alcoholism 
b. Dihydrofolate  reductase inhibitors: Methotrexate, pentamidine, trimethoprim 
5. Reduced hepatic stores 
a. Alcoholism 
b. Chronic liver disease and cirrhosis 
c. Hepatic malignancy 
5.3 Alcoholism 
The common cause of Folate deficiency is alcohol intake. Folate deficiency in alcoholics can 
be attributed to multiple factors.  
a. Dietary malabsorption 
b. Reduced food intake 
c. Depletion of liver stores of folate 
d. Impaired intracellular folate utilization 
Prolonged and excessive alcohol can lead to megaloblastic changes in the bone marrow.  
5.4 Tropical sprue / coeliac disease 
In tropical sprue and coeliac disease, low folate levels are caused by folate malabsorption.  
Steatorrhoea is the major symptom. 
In tropical sprue there will be high foecal fat and jejunal biopsy shows subtotal or total 
villous atrophy. In coeliac disease, d- xylose test is positive.  
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In coeliac disease, a gluten free diet can correct folate malabsorption. 
5.5 Anti convulsant drugs 
Drugs like phenytoin and phenobarbitone can cause folate deficiency. This is usually due to 
inhibition of dietary folate absorption caused by reduced levels of small intestinal 
conjugases. 
5.6 Pregnancy 
Since the foetus accumulates folate, the demand is high during pregnancy. 
5.7 Haemolytic states 
Haemolytic states like hereditary spherocytosis, auto-immune haemolytic anaemia, sickle 
cell anaemia, thalassaemias and paroxysmal nocturnal haemoglobinuria cause erythroid 
hyperplasia. Increased erythroid turnover causes an increase in folate demand, thus causing 
folate deficiency.  
5.8 Exfoliative disorders 
Patients can lose folate in exfoliated skin. In exfoliative skin disorders, folate deficiency can 
occur. 
5.9 Neoplastic disorders 
In acute leukaemias, myeloproliferative disorders, myeloma and metastatic carcinomas, the 
neoplastic tissue utilize folate more rapidly than the host tissue. 
5.10 Clinical features of folate deficiency 
Clinical features of folate deficiency are similar to cobalamin deficiency, except that 
neurological manifestations are not common in folate deficiency. 
Haematological – pancytopenia with megaloblastic anaemia 
Cardiopulmonary - congestive heart failure 
Gastrointestinal – glossitis, broad spectrum malabsorption and diarrhoea 
Folate deficiency can also be implicated in:  
1. Increased arteriosclerosis risks due to elevated homocysteine1 
2. Foetal neural tube defects2  
3. Cancer pathogenesis3 
5.11 Laboratory investigations 
5.11.1 Full blood count & blood film 
The features are similar to cobalamin deficiency. Macrocytic anaemia with ovalocytes and 
tear drop cells are seen in the blood film. Hypersegmented neutrophils are commonly seen. 
Neutropenia and thrombocytopenia are less common. In rare cases, the absolute neutrophil 
count can drop below 1.0 x 109/L and the platelet count below 50 x 109/L. 
5.11.2 Bone marrow analysis 
Bone marrow features are also similar to that seen in cobalamin deficiency. Hypercellularity 
is prominent in all the three cell lines. Erythroid hyperplasia is more marked than the others. 
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Abnormal erythropoiesis with abnormally large red cell precursors (megaloblasts) with less 
mature nuclei (nuclear – cytoplasmic asynchrony) is common.  
5.11.3 Serum folate levels 
Normal serum folate levels are 7-45 nmol/L measured by immunoassay. 
Limitations of serum folate assay: 
Levels vary with levels of folate in the recent diet. Falsely high values of serum folate can 
occur in haemolysis (in vivo and in vitro) and in cobalamin deficiency. 
5.11.4 Red cell folate levels 
Normal serum folate levels are 360-1400 nmol/L, measured by immunoassa. Red cell folate 
is a good index of folate stores and not affected by dietary folate intake. Low red cell folate 
levels are a better predictor for folate deficiency than low serum folate levels. 
However, there are few limitations in this assay. Low to subnormal range occurs only after all 
the stores are depleted. In two-thirds of patients with severe cobalamin deficiency, falsely low 
red cell folate levels are common.  Since reticulocytes have increased folate concentrations, 
haemolytic states may produce falsely normal or high red cell folate despite folate deficiency.  
5.11.5 Serum homocysteine and methyl malonic acid 
In folate deficiency, serum methyl malonic acid levels are normal and homocysteine levels 
are high.4 
6. Treatment of folate deficiency 
The usual treatment dose of folic acid tablets is 1mg/day.  Sometimes up to 5mg/day may be 
required as in haemolytic anaemias. Adequate absorption with such doses usually occurs even 
in chronic folate malabsorption. Therapy should be continued until complete hematologic 
recovery. If the underlying cause is not correctable, folate should be continued. Folinic acid 
(leucovorin) can be used to rescue drugs with antifolate activity e.g. antimetabolites 
(methotrexate or 5-fluorouracil) or other drugs like sulfamethoxazole- trimethoprim and 
pentamidine. Haematological response after folate is similar to cobalamin deficiency. 
6.1 Prophylaxis 
Folic acid prophylaxis is essential in the following situations 
a. Pregnancy and lactation: The dose is usually 400mcg daily. 
b. Mothers at risk of delivery of neural tube defects: The dose of folic acid is 4mg/day 
during the peri-conception period and throughout the first trimester. 
c. Haemolytic anemias  and hyperproliferative haematological states: The dose is usually 
between 1mg to 5mg daily. 
d. Patients with rheumatoid arthritis or psoriasis on medication with methotrexate.6 
7. Other rare nutritional deficiencies that can cause anaemia 
Deficiencies of trace elements like copper and selenium can cause anaemia. 
Copper is present in legumes, meats, and nuts with a very low daily requirement.1 It is 
absorbed through the mucosa of the stomach and proximal duodenum.2  
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Copper is an essential trace metal acting as a ligand to many proteins and enzymes.2 
Dopamine ß-hydroxylase is a copper containing enzyme responsible for conversion of 
dopamine to norepinephrine, which mediates many neurologic functions. Copper also acts 
as a ligand to ferroxidase II, which oxidizes iron, helping in the mobilization and transport 
from hepatic stores to the bone marrow for erythropoiesis.3 Thus, copper deficiency results 
in excessive iron in the liver but defective transport of iron to the marrow for effective 
erythropoiesis.4 
7.1 Causes of copper
 
deficiency 
Acquired copper deficiency is rare. The few potential causes are 
1. Gastric and bariatric surgery causing malabsorption5,6  
2. Intravenous hyperalimentation without copper supplementation 
3. Hyperzincaemia 
4. Menkes disease, an inherited copper deficiency disorder, in which there is a failure of 
transporting absorbed copper to the rest of the body from mucosal cells. 
7.2 Haematological manifestations of copper deficiency 
Copper deficiency can cause anaemia and leukopenia. Sideroblastic changes and nuclear 
maturation defects in erythroid precursors leading to anaemia have been observed in 
patients with copper deficiency.1 Peripheral smear often reveals sideroblastic anaemia with 
hypochromic microcytic red cells. Leucopenia and thrombocytopenia are less common.7 The 
MCV is normal or increased in anaemia of copper deficiency. 
7.3 Other manifestations 
Copper deficiency is known to cause neurologic deficits due to demyelination. 
Manifestations include myelopathy, polyneuropathy, ataxia and optic neuritis.8  The 
combination of myelopathy, polyneuropathy and anaemia in copper deficiency can mimic 
the deficits seen with vitamin B12 deficiency. 
7.4 Treatment 
Copper deficiency can be treated with either oral copper supplementation 
or intravenous copper.9 If zinc intoxication is present, discontinuation of zinc may be 
sufficient to restore copper levels back to normal, but this is usually a very slow 
process.9 They will also need to take copper supplements in addition to stopping zinc 
consumption. Haematological manifestations are often quickly restored back to 
normal.9 The neurological symptoms will often cease, but the symptoms are not always 
restored back to normal. 
7.5 Selenium 
Selenium is a vital trace element for efficient and effective operation of many functions of 
the human immune system.10,11  Selenium is a mineral that is required by the body in trace 
amounts. Daily requirement of selenium is 50 micrograms. It is present in most organs of the 
body like kidneys, spleen, liver, pancreas. Selenium is a component of glutathione 
peroxidase and can be used as an antioxidant and also plays a large role in cell metabolism 
and cancer prevention.  
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7.5.1 Selenium deficiency 
Selenium deficiency is relatively rare in healthy well-nourished individuals.  
Causes of selenium deficiency 
1. Eating foods predominantly grown in selenium-deficient soil.  
2. Severely compromised intestinal function  
3. Total parenteral nutrition 
4. Gastrointestinal bypass surgery 
Manifestations of a selenium deficiency include cardiovascular disease, nerve degeneration, 
hypothyroidism, arthritis and anaemia. A selenium deficiency may even increase the 
chances of developing some forms of cancer.  
Selenium deficiency may play a role in causing or aggravating anaemia as glutathione 
peroxidase protects red blood cells from free radical damage and destruction. In a prevalence 
study there was low serum selenium found independently associated with anaemia among 
older men and women.12 Mean serum selenium among non-anaemic and anaemic adults was 
1.60 and 1.51 umol /L (P=0.0003). The prevalence of anaemia among adults in the lowest to 
highest quartiles of serum selenium was 18.3, 9.5, 9.7 and 6.9%, respectively (P=0.0005).12 
7.5.2 Supplements 
There are many forms of selenium supplements including organic selenium rich yeast, 
selenium in the form of selenomethionine, and inorganic sodium selenite. Selenium yeast 
increases the blood selenium levels and sodium selenite helps to increase the activity of 
glutathione peroxidase. Organic selenium is better absorbed and less toxic than the inorganic 
forms. People who are at risk of selenium deficiency will benefit from supplements. 
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